TWI612042B - 環烷衍生物及其使用 - Google Patents

環烷衍生物及其使用 Download PDF

Info

Publication number
TWI612042B
TWI612042B TW102104725A TW102104725A TWI612042B TW I612042 B TWI612042 B TW I612042B TW 102104725 A TW102104725 A TW 102104725A TW 102104725 A TW102104725 A TW 102104725A TW I612042 B TWI612042 B TW I612042B
Authority
TW
Taiwan
Prior art keywords
oxy
pyrazol
pyrimidin
benzenesulfonamide
methyl
Prior art date
Application number
TW102104725A
Other languages
English (en)
Chinese (zh)
Other versions
TW201339152A (zh
Inventor
篠塚剛
小林宏行
鈴木沙也加
田中教介
木本裕子
土門友紀
Original Assignee
第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共股份有限公司 filed Critical 第一三共股份有限公司
Publication of TW201339152A publication Critical patent/TW201339152A/zh
Application granted granted Critical
Publication of TWI612042B publication Critical patent/TWI612042B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102104725A 2012-02-09 2013-02-07 環烷衍生物及其使用 TWI612042B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012-025754 2012-02-09
JP2012-259122 2012-11-27
JP2012259122 2012-11-27

Publications (2)

Publication Number Publication Date
TW201339152A TW201339152A (zh) 2013-10-01
TWI612042B true TWI612042B (zh) 2018-01-21

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102104725A TWI612042B (zh) 2012-02-09 2013-02-07 環烷衍生物及其使用

Country Status (30)

Country Link
US (3) US8889741B2 (Direct)
EP (2) EP3144300B1 (Direct)
JP (2) JP5997710B2 (Direct)
KR (1) KR20140127238A (Direct)
CN (1) CN104185629B (Direct)
AU (1) AU2013218592B2 (Direct)
BR (1) BR112014019478A2 (Direct)
CA (1) CA2864222C (Direct)
CO (1) CO7151511A2 (Direct)
CY (1) CY1118572T1 (Direct)
DK (1) DK2813491T3 (Direct)
ES (2) ES2613078T3 (Direct)
HR (1) HRP20161713T1 (Direct)
HU (2) HUE037048T2 (Direct)
IL (1) IL234014A (Direct)
IN (1) IN2014MN01577A (Direct)
LT (1) LT2813491T (Direct)
MX (1) MX349354B (Direct)
NZ (1) NZ628096A (Direct)
PH (2) PH12014501804A1 (Direct)
PL (1) PL2813491T3 (Direct)
PT (1) PT2813491T (Direct)
RS (1) RS55671B1 (Direct)
RU (1) RU2635354C2 (Direct)
SG (1) SG11201404707VA (Direct)
SI (1) SI2813491T1 (Direct)
SM (2) SMT201700053T1 (Direct)
TW (1) TWI612042B (Direct)
WO (1) WO2013118854A1 (Direct)
ZA (1) ZA201405801B (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630204B (zh) * 2013-03-14 2018-07-21 第一三共股份有限公司 呼吸器官疾病用藥

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
PE20150400A1 (es) 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
MX2015011436A (es) 2013-03-14 2016-06-06 Genentech Inc Triazolopiridinas sustituidas y metodos para usarlas.
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10179767B2 (en) 2015-05-22 2019-01-15 Genentech, Inc. Substituted benzamides and methods of use thereof
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
KR20180080187A (ko) * 2015-11-06 2018-07-11 다이이찌 산쿄 가부시키가이샤 디메톡시벤질기의 탈리 방법
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック, インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3458449B1 (en) * 2016-05-20 2025-03-05 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR20190078587A (ko) * 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
KR102561076B1 (ko) * 2016-10-27 2023-07-28 브리스톨-마이어스 스큅 컴퍼니 아실 술폰아미드 NaV1.7 억제제
AU2017371674B2 (en) * 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
KR102796209B1 (ko) 2017-09-20 2025-04-16 에이비엠 쎄라퓨틱스 코포레이션 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
UA127024C2 (uk) 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MX2021007425A (es) 2018-12-26 2021-08-05 Raqualia Pharma Inc Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
CN102348697A (zh) * 2009-01-12 2012-02-08 辉瑞股份有限公司 磺酰胺衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
MX2007014486A (es) * 2005-05-16 2008-02-12 Vertex Pharma Derivados biciclicos como moduladores de canales ionicos.
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
CA2804593C (en) * 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
US9145407B2 (en) * 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドPfizer Limited 化合物
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
CN102348697A (zh) * 2009-01-12 2012-02-08 辉瑞股份有限公司 磺酰胺衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630204B (zh) * 2013-03-14 2018-07-21 第一三共股份有限公司 呼吸器官疾病用藥

Also Published As

Publication number Publication date
ZA201405801B (en) 2015-12-23
LT2813491T (lt) 2017-02-10
CN104185629B (zh) 2017-10-13
PT2813491T (pt) 2017-02-10
SMT201700053B (it) 2017-03-08
HRP20161713T1 (hr) 2017-02-10
JP6154052B2 (ja) 2017-06-28
HK1203503A1 (en) 2015-10-30
US20140045862A1 (en) 2014-02-13
JP5997710B2 (ja) 2016-09-28
CO7151511A2 (es) 2014-12-29
HUE031450T2 (en) 2017-07-28
IL234014A0 (en) 2014-09-30
RU2014136463A (ru) 2016-03-27
ES2613078T3 (es) 2017-05-22
EP2813491A1 (en) 2014-12-17
BR112014019478A2 (pt) 2019-05-28
CA2864222C (en) 2016-10-25
IL234014A (en) 2017-09-28
CY1118572T1 (el) 2017-07-12
MX349354B (es) 2017-07-24
SI2813491T1 (sl) 2017-02-28
IN2014MN01577A (Direct) 2015-05-08
SMT201700053T1 (it) 2017-03-08
AU2013218592B2 (en) 2016-12-22
AU2013218592A1 (en) 2014-09-18
US20170001984A1 (en) 2017-01-05
PH12014501804B1 (en) 2014-11-17
RU2635354C2 (ru) 2017-11-13
US9493448B2 (en) 2016-11-15
RS55671B1 (sr) 2017-06-30
NZ628096A (en) 2016-06-24
JPWO2013118854A1 (ja) 2015-05-11
EP3144300A1 (en) 2017-03-22
US8889741B2 (en) 2014-11-18
PL2813491T3 (pl) 2017-08-31
TW201339152A (zh) 2013-10-01
PH12014501804A1 (en) 2014-11-17
WO2013118854A1 (ja) 2013-08-15
DK2813491T3 (en) 2017-02-13
PH12015502675A1 (en) 2017-04-24
EP3144300B1 (en) 2017-12-20
EP2813491A4 (en) 2015-08-12
JP2017008093A (ja) 2017-01-12
EP2813491B1 (en) 2016-11-02
CA2864222A1 (en) 2013-08-15
HUE037048T2 (hu) 2018-08-28
US9845313B2 (en) 2017-12-19
MX2014009637A (es) 2015-06-23
CN104185629A (zh) 2014-12-03
SG11201404707VA (en) 2014-10-30
ES2659434T3 (es) 2018-03-15
KR20140127238A (ko) 2014-11-03
US20150018551A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
TWI612042B (zh) 環烷衍生物及其使用
TWI494317B (zh) 磺醯胺衍生物
CN115298170A (zh) 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物
TWI606039B (zh) Apj受體之三唑激動劑
TWI630204B (zh) 呼吸器官疾病用藥
TWI471132B (zh) 2-吡啶酮化合物
TW202039474A (zh) 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法
HK40087589B (zh) Cd38抑制剂
HK40087589A (zh) Cd38抑制剂
HK1161253B (en) Sulfonamide derivatives

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees